Home / Business and Economy / Value Investor Bets Big on Biotech and Telecom in Latest 13F Filing
Value Investor Bets Big on Biotech and Telecom in Latest 13F Filing
14 Nov
Summary
- Firm added major positions in Becton Dickinson and Uniti Group
- Significantly increased stakes in Thermo Fisher Scientific and Avantor
- Completely exited 3 holdings in Q3 2025
On November 14, 2025, value-focused investment firm First Pacific Advisors (Trades, Portfolio) filed its 13F report for the third quarter of 2025, providing insights into its recent investment activities. The Los Angeles-based firm, known for its concentrated, research-intensive approach, made several notable moves during the quarter.
The most significant addition to First Pacific's portfolio was a 936,257-share position in Becton Dickinson & Co (NYSE:BDX), valued at $175.24 million and accounting for 2.46% of the overall portfolio. The firm also added a 25,235-share stake in Uniti Group Inc (NASDAQ:UNIT), worth approximately $154,440.
In addition to these new buys, First Pacific significantly increased its existing positions. The most notable increase was in Thermo Fisher Scientific Inc (NYSE:TMO), with an additional 127,576 shares, bringing the total to 214,946 shares. This 146.02% increase represented an $104.25 million investment. The firm also added nearly 4 million shares of Avantor Inc (NYSE:AVTR), a 5,327.97% increase, valued at $50.81 million.
Alongside these additions and increases, First Pacific Advisors completely exited 3 holdings during the third quarter of 2025. The firm's concentrated, value-oriented approach continues to shape its investment decisions as it navigates the evolving market landscape.
